Payment overview · 2025
General Payments
$1,102.38
54 reported records · 23 companies
Healthcare provider profile · identity verified
Thomas D Gilberts, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BEAVERTON, OR · NPI 1841214236
Verified facts
What the public records show
CMS Open Payments records show Thomas D Gilberts, MD received $1,102.38 in general payments during 2025 across 54 reported records.
Amgen Inc. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.24 | 15.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $155.06 | 14.1% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.35 | 6.3% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $69.03 | 6.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.74 | 5.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.39 | 5.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.35 | 4.8% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $51.99 | 4.7% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.38 | 4.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.03 | 4.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.00 | 3.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.90 | 3.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.82 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.15 | 3.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.13 | 2.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.83 | 1.9% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.21 | 1.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.01 | 1.7% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $16.85 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.87 | 1.4% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $15.60 | 1.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $13.90 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.55 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,102.38 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $173.24 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $130.93 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $130.93 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.35 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $69.03 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.74 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $53.35 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.38 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| Event Normalized: event |
Device | Philips North America LLC | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $33.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| PANHEMATIN Normalized: panhematin |
Drug | RECORDATI_RARE_DISEASES_INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 573 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 115 |
| Lisinopril | Lisinopril | 404 | 112 |
| Omeprazole | Omeprazole | 404 | 97 |
| Gabapentin | Gabapentin | 308 | 87 |
| Losartan Potassium | Losartan Potassium | 272 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 80 |
| Metformin Hcl | Metformin Hcl | 233 | 68 |
| Potassium Chloride | Potassium Chloride | 231 | 56 |
| Trazodone Hcl | Trazodone Hcl | 220 | 44 |
| Simvastatin | Simvastatin | 182 | 53 |
| Furosemide | Furosemide | 181 | 41 |
| Buspirone Hcl | Buspirone Hcl | 159 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 46 |
| Carvedilol | Carvedilol | 157 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 26 |
| Sertraline Hcl | Sertraline Hcl | 136 | 32 |
| Alendronate Sodium | Alendronate Sodium | 128 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 22 |
| Tramadol Hcl | Tramadol Hcl | 114 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 48 |
| Donepezil Hcl | Donepezil Hcl | 111 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 27 |
| Metformin Hcl Er | Metformin Hcl | 102 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 18 |
| Montelukast Sodium | Montelukast Sodium | 91 | 18 |
| Farxiga | Dapagliflozin Propanediol | 90 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Lorazepam | Lorazepam | 77 | 19 |
| Atenolol | Atenolol | 76 | 21 |
| Glipizide Er | Glipizide | 76 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 19 |
| Eliquis | Apixaban | 69 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 18 |
| Xarelto | Rivaroxaban | 68 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 13 |
| Pregabalin | Pregabalin | 62 | 15 |
| Alprazolam | Alprazolam | 61 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 25 |
| Mupirocin | Mupirocin | 55 | 44 |
| Prednisone | Prednisone | 55 | 23 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 22 |
| Lovastatin | Lovastatin | 47 | 11 |
| Ozempic | Semaglutide | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | 13 |
| Allopurinol | Allopurinol | 44 | 16 |
| Famotidine | Famotidine | 44 | 12 |
| Glipizide | Glipizide | 44 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 14 |
| Cephalexin | Cephalexin | 38 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Nystatin | Nystatin | 34 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 17 |
| Olanzapine | Olanzapine | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Valsartan | Valsartan | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rybelsus | Semaglutide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,102.38 · 54 records | Amgen Inc. | AIRSUPRA, AREXVY, CRYSVITA, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, Event, GVOKE HYPOPEN, INJECTAFER, JOURNAVX, KISUNLA, Kerendia, Korlym, Leqembi, MAVYRET, MCOT, NURTEC ODT, Ozempic, PANHEMATIN, REXULTI, REZDIFFRA, Rybelsus, SMARTVEST, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error